Related Experiment Video
Updated: May 13, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Farnesyl Transferase Inhibitors as a Novel Strategy for Targeting KRAS-Dependent Cancers
1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
Abstract:
KRAS mutations drive tumorigenesis in multiple cancers, yet direct inhibitors display limited efficacy due to adaptive resistance. Recent preclinical findings indicate farnesyl transferase inhibitors (FTIs) can reduce compensatory mTOR and MAPK pathway activation. Evidence supports combining FTIs with KRAS inhibitors to enhance tumor suppression and delayed resistance.
Insights
Combining farnesyl transferase inhibitors (FTIs) with KRAS inhibitors may overcome adaptive resistance in cancer. This approach shows promise for enhancing tumor suppression and delaying treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS mutations are key drivers in numerous cancers.
- Direct KRAS inhibitors face challenges with adaptive resistance, limiting clinical efficacy.
- Compensatory signaling pathways, including mTOR and MAPK, contribute to resistance.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Treatment Resistant Cancers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
The Ras Gene
Ras is a...

